Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas

Oncogene

Volumn 32, Issue 9, 2013, Pages 1091-1098

  Sarek, G ^a   Ma, L ^a   Enback J ^b   Jarviluoma A ^c   Moreau, P ^d   Haas, J ^e,f   Gessain, A ^g   Koskinen, P J ^h   Laakkonen, P ^b,i   Ojala, P M ^a,j  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF MUNICH   (Germany)

^g INSTITUT PASTEUR   (France)

^h UNIVERSITY OF TURKU   (Finland)

ⁱ K Albin Johansson Foundation   (Finland)

^j Finnish Cancer Institute   (Finland)

more..

Author keywords

apoptosis; hypoxia; KSHV; lymphoma; p53; viral lytic replication

Indexed keywords

CARBONATE DEHYDRATASE IX; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; NUTLIN 3; PHORBOL ESTER; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 3; PROTEIN P53; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN HERPESVIRUS 8; IN VIVO STUDY; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT; VIRUS INHIBITION; VIRUS REACTIVATION; VIRUS REPLICATION;

APOPTOSIS; GENES, P53; HERPESVIRUS 8, HUMAN; HUMANS; IMIDAZOLES; LYMPHOMA, PRIMARY EFFUSION; PERITONEAL NEOPLASMS; PIPERAZINES; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS; VIRUS ACTIVATION; VIRUS REPLICATION;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

EID: 84874715039     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.118     Document Type: Article

References (48)

1. Ablashi DV, Chatlynne LG, Whitman Jr JE, Cesarman E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 2002; 15: 439-464.
2. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88: 645-656.
3. Cesarman E, Nador RG, Aozasa K, Delsol G, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol 1996; 149: 53-57.
4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcomaassociated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332: 1186-1191.
5. Casper C. New approaches to the treatment of human herpesvirus 8-associated disease. Rev Med Virol 2008; 18: 321-329.
6. Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-4380.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
8. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
9. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
10. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
11. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893.
12. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-3159.
13. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609-3617.
14. Carbone A, Cilia AM, Gloghini A, Capello D, Todesco M, Quattrone S et al. Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol 1998; 102: 1081-1089.
15. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007; 117: 1019-1028.
16. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ et al. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 2006; 107: 3295-3302.
17. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1998; 95: 10866-10871.
18. Chandran B, Bloomer C, Chan SR, Zhu L, Goldstein E, Horvat R. Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. Virology 1998; 249: 140-149.
19. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96: 2537-2542.
20. Grossmann C, Ganem D. Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. Virology 2008; 375: 94-102.
21. Scott ML, Fujita T, Liou HC, Nolan GP, Baltimore D. The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev 1993; 7: 1266-1276.
22. Morotti A, Cilloni D, Pautasso M, Messa F, Arruga F, Defilippi I et al. NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. Am J Hematol 2006; 81: 938-945.
23. Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, Tosato G et al. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 2001; 97: 3244-3250.
24. Haque M, Davis DA, Wang V, Widmer I, Yarchoan R. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia. J Virol 2003; 77: 6761-6768.
25. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001; 61: 6394-6399.
26. Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003; 73: 143-148.
27. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21: 3948-3954.
28. Qin Z, Dai L, Bratoeva M, Slomiany MG, Toole BP, Parsons C. Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma. Leukemia 2011; 25: 1598-1609.
29. Wies E, Hahn AS, Schmidt K, Viebahn C, Rohland N, Lux A et al. The Kaposi's sarcoma-associated Herpesvirus-encoded vIRF-3 inhibits cellular IRF-5. J Biol Chem 2009; 284: 8525-8538.
30. Nakamura H, Lu M, Gwack Y, Souvlis J, Zeichner SL, Jung JU. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol 2003; 77: 4205-4220.
31. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcomaassociated herpesvirus lymphomas: implications for therapy. J Virol 2007; 81: 1912-1922.
32. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99: 2082-2086.
33. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R. Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi's sarcoma-associated herpesvirus infected cells. Cancer Res 2007; 67: 7003-7010.
34. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10(Suppl 3): S490-S494.
35. Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). Adv Exp Med Biol 1996; 394: 105-115.
36. Nicholas J. Human gammaherpesvirus cytokines and chemokine receptors. J Interferon Cytokine Res 2005; 25: 373-383.
37. Varjosalo M, Bjorklund M, Cheng F, Syvanen H, Kivioja T, Kilpinen S et al. Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell 2008; 133: 537-548.
38. Cheng F, Weidner-Glunde M, Varjosalo M, Rainio EM, Lehtonen A, Schulz TF et al. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog 2009; 5: e1000324.
39. Akue-Gedu R, Rossignol E, Azzaro S, Knapp S, Filippakopoulos P, Bullock AN et al. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009; 52: 6369-6381.
40. Santio NM, Vahakoski RL, Rainio EM, Sandholm JA, Virtanen SS, Prudhomme M et al. Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer 2010; 9: 279.
41. Brown HJ, McBride WH, Zack JA, Sun R. Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther 2005; 10: 745-751.
42. Dittmer DP. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res 2003; 63: 2010-2015.
43. Ganem D. KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 2006; 1: 273-296.
44. Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. Aids 2006; 20: 1567-1569.
45. Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. Aids 2001; 15: 280-282.
46. Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005; 19: 473-476.
47. Katano H, Sato Y, Kurata T, Mori S, Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269: 335-344.
48. Sarek G, Jarviluoma A, Ojala PM. KSHV viral cyclin inactivates p27KIP1 through Ser10 and Thr187 phosphorylation in proliferating primary effusion lymphomas. Blood 2006; 107: 725-732.